Tellgen Corp Asset Resilience Ratio
Tellgen Corp asset resilience ratio. Tellgen Corp (300642) has an Asset Resilience Ratio of 12.10% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tellgen Corp (300642) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tellgen Corp (2017–2025)
Asset resilience ratio of Tellgen Corp from 2017 to 2025. This chart shows how Tellgen Corp's Asset Resilience Ratio has changed over time. Read debt load of Tellgen Corp for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tellgen Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Tellgen Corp asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥243.62 Million | 12.1% |
| Total Liquid Assets | CN¥243.62 Million | 12.10% |
Asset Resilience Insights
- Moderate Liquidity: Tellgen Corp has 12.10% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Tellgen Corp Industry Peers by Asset Resilience Ratio
Compare Tellgen Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Tellgen Corp Asset Resilience Ratio by Year (2017–2025)
Tellgen Corp asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Tellgen Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.29% | CN¥170.57 Million ≈ $24.96 Million |
CN¥2.06 Billion ≈ $300.98 Million |
-2.10pp |
| 2024-12-31 | 10.39% | CN¥181.75 Million ≈ $26.60 Million |
CN¥1.75 Billion ≈ $255.93 Million |
+4.26pp |
| 2023-12-31 | 6.13% | CN¥103.02 Million ≈ $15.07 Million |
CN¥1.68 Billion ≈ $245.80 Million |
-9.54pp |
| 2022-12-31 | 15.67% | CN¥260.88 Million ≈ $38.17 Million |
CN¥1.66 Billion ≈ $243.60 Million |
-2.43pp |
| 2021-12-31 | 18.10% | CN¥271.35 Million ≈ $39.71 Million |
CN¥1.50 Billion ≈ $219.33 Million |
+0.33pp |
| 2020-12-31 | 17.77% | CN¥243.77 Million ≈ $35.67 Million |
CN¥1.37 Billion ≈ $200.73 Million |
-5.62pp |
| 2019-12-31 | 23.39% | CN¥291.60 Million ≈ $42.67 Million |
CN¥1.25 Billion ≈ $182.40 Million |
+23.89pp |
| 2018-12-31 | -0.50% | CN¥-5.47 Million ≈ $-800.28K |
CN¥1.10 Billion ≈ $161.38 Million |
+0.18pp |
| 2017-12-31 | -0.68% | CN¥-6.37 Million ≈ $-931.69K |
CN¥935.16 Million ≈ $136.84 Million |
-- |
About Tellgen Corp
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in… Read more